Evidence map›Paper›PMID 34149081›Full record

ArticleMissouri medicine

Fish Oil Supplements for Prevention of Cardiovascular Disease: The Jury Is Still Out: CON: Fish Oil is Useful to Prevent or Treat Cardiovascular Disease.

Hekmat B Khoukaz, William P Fay

Open access · greenAbstract read
In one paragraph

Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hekmat B KhoukazDepartment of Medicine.
William P FayDepartments of Medicine and Medical Pharmacology and Physiology, University of Missouri- Columbia School of Medicine, Columbia, Missouri. Dr. Fay is also in Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri.
Harry S. Truman Memorial Veterans' Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Consumption of oily fish high in omega-3 fatty acids (n-3FAs) is strongly associated with reduced risk of adverse cardiovascular events. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the n-3FAs in fish oil believed to confer its beneficial effects. Over the past two decades, multiple clinical trials have been conducted to test the hypothesis that encapsulated EPA and DHA supplements improve cardiovascular outcomes in patients with established cardiovascular disease or at risk of developing it. Over the same time period, over-the-counter fish oil supplements have become a multi-billion-dollar industry. In this article, we briefly review available clinical trial data involving EPA and DHA supplementation. Based on currently available information, we conclude that combination capsules containing EPA and DHA should not be used to reduce cardiovascular risk. Some studies suggest that EPA as stand-alone therapy decreases cardiovascular risk. Nevertheless, we advocate a restrictive approach to using EPA to improve cardiovascular outcomes.

Indexed as

Cardiovascular DiseasesFatty Acids, Omega-3Dietary SupplementsDocosahexaenoic AcidsFish OilsHumansDocosahexaenoic AcidsFatty Acids, Omega-3Fish Oils

Identifiers

PMID34149081
PMCPMC8211000
OpenAlexW3177496741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.